Aprea Therapeutics reports FY2023 net loss $14.3M ($3.95/share); cash $21.6M; IND cleared for APR-1051

Aprea Therapeutics, Inc.

Cash and equivalents $21.6M at Dec 31, 2023; combined with $16M Mar 2024 private placement funds into Q3 2025.
Net loss FY2023 $14.3M ($3.95/basic share) vs $112.7M in FY2022 which included $76M acquired IPR&D charge.
ATRN-119 Phase 1/2a dose escalation on track for 4Q 2024 completion; initial efficacy data expected H2 2024.
FDA cleared IND for APR-1051 (WEE1 inhibitor); Phase 1 ACESOT-1051 trial to start H1 2024.
Operating loss $15.5M in FY2023 vs $113.4M in FY2022; R&D expenses fell to $7.6M from $16.4M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.